{
  "docId": "019de072-7781-7512-96cc-a2b05ce755c7",
  "docSlug": "b1746432eb5f270eac90273cddb862aa",
  "documentTitle": "Bionomics | Investor Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 38,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a pharmacokinetic chart showing concentration vs time for different doses.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7781-7512-96cc-a2b05ce755c7/12",
  "deckHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7",
  "deckJsonHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7.json",
  "deckAnchorHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.15,
        "x": 0.5,
        "y": 0.45
      },
      "kind": "callout",
      "text": "Maximum concentrations reached in ~45 – 105 min. across the dose range",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61813440-046c-44f4-be1a-ec6a2efac8fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.65,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Concentration versus Time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12a31357-f890-4c26-b88b-90cd3c8fea93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.14,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*Based on path of CNS peer proceeding with registrational Phase 3 endpoint",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a9c3f16-dae3-4ab2-8ded-11a1612dbd07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "list",
      "text": "Emerging Regulatory Landscape & Unmet Need: Benzodiazepines prescribed off-label have significant side effects; Growing unmet need; FDA precedent on simplified public speaking challenge endpoint.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "192cc429-0b43-43cc-af09-3c530f6e5de8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.47,
        "x": 0.49,
        "y": 0.14
      },
      "kind": "list",
      "text": "Rapid Onset of Action with BNC210 Formulation: Clinically demonstrated potential for reducing anxiety; Observed acute anxiolytic efficacy similar to lorazepam; Formulation well-suited for acute dosing.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8523b0c-e94e-450a-a185-9bca4534cfff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.075,
        "y": 0.03
      },
      "kind": "title",
      "text": "BNC210's Rapid Onset of Action is Well-Positioned for Social Anxiety Disorder",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45da1d5d-fe2d-4d13-9222-211577782080",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "526cdb64-5721-4dd6-8960-cf5197ca0acc",
      "evidence": "list/bullet: Rapid Onset of Action with BNC210 Formulation: Clinically demonstrated potential for reducing anxiety; Observed acute anxiolytic efficacy similar to lorazepam; Formulation well-suited for acute dosing.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 12,
      "beatId": "5a730e5a-abd5-4b84-8096-b3f5be8f655b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Why Now",
      "beatSlug": "sequoia-pitch-why-now",
      "evidence": "The why now section is presented on page 12, highlighting BNC210's rapid onset of action and its potential in Social Anxiety Disorder.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}